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Background: This study aimed to assess the safety and effectiveness of different dosages of heparin for
adhesion prevention by comparing with Sepraﬁlm, in a murine model.
Materials and methods: Seventy ﬁve Balb/c mice were randomized into ﬁve groups. Group C were
reserved as controls, and 62.5 IU, 125 IU, 250 IU of heparin, and Sepraﬁlmwere intraperitoneally applied
in studied groups. The severity and locations of adhesions were assessed after the sacriﬁcation on day 14.
The cause of death was investigated to evaluate the side effects of the drugs.
Results: The death of 2 subjects due to peritonitis (1 in Group C, 1 in Group H62.5) left 14 subjects in
Group C and Group H62.5 (P  0.05), and no hemorrhage related death was observed. The use of the
products signiﬁcantly reduced the severity score of adhesion and the number of animals, had adhesions
in different locations of the abdominal cavity, when the results were compared with the control group
(P < 0.05 for all comparisons). Higher dosages of heparin seemed to be more effective. The results in
group S, groups H250 and H125 were quite similar.
Conclusions: Relatively high doses (125 IU and 250 IU) of intra-abdominal heparin may be comparable in
safety and effectiveness to Sepraﬁlm in adhesion prevention in mice.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Postoperative intra-abdominal adhesions are accepted as
a regular consequence of surgical intervention and occur after
almost all abdominal procedures, ranging from 67 to 93% of all
operations, thus believed to be one of the most challenging
problems in current medical practice.1 Although most of the post-
operative adhesions do not cause any further complications,
studies have revealed that intra-abdominal adhesions are respon-
sible for 50e70% of hospitalizations due to small bowel obstruction.
Other sequelas of adhesion related morbidity include chronic
abdominal pain and female infertility.2e5 They may also increase
the risk of inadvertent visceral injuries during the entry to the
abdomen; accordingly lengthen the operation time in case of a
subsequent laparotomy. Finally, these complications incur consid-
erable economic costs.3,6a Hastanesi, Cevizli, 34860,
t).
ciates Ltd. Published by Elsevier LtSepraﬁlm is a sterile, bioresorbable, translucent adhesion
barrier composed of sodium hyaluronate and carboxymethyl
cellulose and acts as a temporary bioabsorbable barrier separating
apposing tissue surfaces. The physical presence of the membrane
separates adhesiogenic tissue while the normal tissue repair
process takes place. The effect of Sepraﬁlm in reducing intra-
abdominal adhesions have been conﬁrmed by experimental and
clinical trials, and it has been accepted as the best choice of
product being used for this purpose.6,7
Heparin is an anticoagulant product that has been widely used
for the prevention and treatment of deep venous thrombosis. Since,
it theoretically stops ﬁbrin formation and consequent adhesio-
genesis, heparin has been extensively monitored for adhesion
prevention in laboratory setting.8 Investigations have revealed
that heparin signiﬁcantly reduces postoperative adhesions.9 The
optimal dose of heparin to be used for the purpose of adhesion
prevention is not known. The favorable dosage of the product
should decrease the severity of intra-abdominal adhesions without
increasing the risk of drug-related complications, particularly
bleeding. Thus, we believe that different dosages deserve to be
reanalyzed in order to ﬁnd out the optimal dose of the drug as an
anti-adhesive product besides carefully addressing the side-effects
of heparin.d. All rights reserved.
Table 1
Mazuji adhesion severity scoring system.10
Grade Description
0 No adhesions
1 Slight adhesions can be separated with blunt dissection
2 Moderate adhesions can be mostly separated with blunt
dissection. but require sharp dissection in less than 50% of the
adhered segments
3 Severe adhesions require sharp dissection in more than 50% of
the adhered segments
4 Presence of serosal injury
5 Presence of full-thickness injury
Table 2
Severity of adhesions and comparisons of the results within the groups.
Grade Group C
(n ¼ 14) (%)
Group H62.5
(n ¼ 14) (%)
Group H125
(n ¼ 15) (%)
Group H250
(n ¼ 15) (%)
Group S
(n ¼ 15) (%)
0 0 (0) 4 (28.6) 9 (60) 9 (60) 10 (66.7)
1 2 (14.3) 5 (35.7) 2 (13.3) 4 (26.7) 3 (20)
2 4 (28.6) 3 (21.5) 3 (20) 2 (13.3) 2 (13.3)
3 5 (35.7) 0 (0) 1 (6.7) 0 (0) 0 (0)
4 1 (7.1) 2 (14.3) 0 (0) 0 (0) 0 (0)
5 2 (14.3) 0 (0) 0 (0) 0 (0) 0 (0)
Overall P < 0.001. P < 0.05 for group 62.5 vs. group C. P < 0.01 for group 125. group
250 and group S vs. group C. P  0.05 for all other comparisons.
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will decrease adhesion severity without any increase in complica-
tion risk. The results are planned to be compared with the data
obtained from subjects who received Sepraﬁlm that has been
accepted the choice of product used for adhesion prevention.2. Materials and methods
The study was approved by Kartal Education and Research Hospital Ethics and
Education Planning Committee (EPK), and operations were performed at Experi-
mental Medicine Research Center (DETAM), Istanbul University Medical School.
A total of 75 Balb/c mice were subjects of the study. Animals were fed with
a standard laboratory diet, given tap water and kept in metal cages at room
temperature. All procedures were performed under clean but non-sterile conditions
by one surgeon (ZC). Anesthesia was achieved with intraperitoneal 30 mg/kg ket-
amine HCL (Ketalar, Parke-Davis, USA) injection during operation and adjuvant
ether inhalation when needed. The abdominal skin was shaved and cleansed with
povidone iodine, and a 15 mm long midline laparotomy was performed. The cecum
was found and exteriorized out of the abdomen. Intra-abdominal adhesions were
created with a multiple abrasion model consisting of meticulous abrasion of the
cecum and a 2 cm-long terminal ileum segment with strokes of a dental toothbrush.
The bleeding was stopped by simple ﬁnger pressure application. Then, the subjects
were randomized into ﬁve groups (15 mice in each group). Animals in groups H62.5,
H125 and H250 intraperitoneally received 62.5 IU, 125 IU and 250 IU heparin
(Nevparin ﬂa., Mustafa Nevzat Ilac San A.S, Istanbul, Turkey) in 2 cc saline. A piece
(10  30 mm) of Sepraﬁlm (Genzyme Biosurgery, Cambridge, MA, USA) was placed
over the viscera under the incision in Group S animals and saline (2 cc) was intra-
peritoneally applied in the Control group (Group C). Animals were marked with
special ear cuts for further identiﬁcation after the closure of the abdominal incision
with double layer sutures. If an animal had died prior to the sacriﬁcation, an im-
mediate autopsy was carried out by the operating surgeon in order to reveal the
cause of death.
Animals were sacriﬁed on day 14 with Phenobarbital overdose. Evaluation was
done via an U-shape abdominal incision by an investigator blinded to the
randomization (MO). The severity of adhesions was evaluated with a scoring system
ranging from 0 to 5 developed by Majuzi (Table 1).10 In addition, the presence/
absence of adhesions was assessed in ﬁve locations: between cecum and cecum
(cecum over itself), cecum and fatty tissue, cecum and small intestine, cecum and
abdominal wall; and cecum and liver11 (Fig. 1). Finally, the total number of adhesion-Fig. 1. Grade 3 adhesions between cecum and small intestine.positive locations among the 5 investigated sites was named as ‘location score’
ranging between 0 and 5, and calculated for each animal. The data were compared
within the groups.
All statistical analyses were performed with SPSS 16.0 for Windows software. In
all sample analyses, means were compared with Tukey’s and Student’s t-tests and
frequency distributions, with Pearson’s chi-squared or KolmogoroveSmirnov tests.
P ¼ 0.05 (two-sided) was considered as the limit of signiﬁcance.
3. Results
The death of 2 animals (2.7 percent) (1 in Group C and 1 in
Group H62.5) left 14 subjects in Group C and Group H62.5 prior to
the sacriﬁcation. The autopsies revealed that peritonitis was the
cause of death in both animals, and no hemorrhage related death
was observed. The mortality rates were not signiﬁcantly different
within the groups (P ¼ 0.544).
The animals in all study groups had signiﬁcantly less adhesions
than those in the control group (P < 0.05 for all comparisons), and
Majuzi Adhesion Severity Scoring System revealed no statistical
difference within the study groups (P  0.05 for all comparisons)
(Table 2). Further analyses were done by questioning different
locations within the abdomen for presence/absence of adhesions.
These analyses showed the superiority of Sepraﬁlm and 3 dif-
ferent dosages of heparin applications over the use of saline in
almost all comparisons (Table 3). Finally, the location scores were
signiﬁcantly less in study groups compared to control group
(P < 0.05 for all comparisons) (Table 4). However, a borderline
statistical signiﬁcance was observed between the comparison of
the locations scores of groups S and H62.5 (P ¼ 0.042). Although no
statistically signiﬁcant difference was seen between the 3 heparin
groups, higher doses seemed to be more effective. The results in
group S and groups H250 and H125 are quite similar (P  0.05 for
all comparisons).
4. Discussion
Postoperative intra-abdominal adhesions are one of the most
challenging problems in current medical practice, since they may
cause subsequent complications including small bowel obstruction,
chronic abdominal pain and female infertility. Search has been long
continued in order to ﬁnd out an effective product, and experi-
mental and clinical studies have revealed that intrabdominal use
of Sepraﬁlmmay be the best choice to prevent adhesions. A recent
multicenter prospective randomized trial has showed that
Sepraﬁlm use may reduce the risk of reoperations due to small
bowel obstructions secondary to intra-abdominal adhesions.12
However, Sepraﬁlm may increase the incidence of some serious
complications including anastomotic leak, peritonitis, abscess or
intra-abdominal sepsis.13 Furthermore, unusual problems such as
postoperative acute aseptic peritonitis have been reported after
Sepraﬁlm application.14 Finally, the cost of the product makes the
operation and hospitalization price more expensive. Thus, search is
continuing in order to ﬁnd out a novel and more effective product
Table 3
Comparison of adhesions’ localizations in groups.
Localization Group C (n ¼ 14) (%) Group H62.5 (n ¼ 14) (%) Group H125 (n ¼ 15) (%) Group H250 (n ¼ 15) (%) Group S (n ¼ 15) (%) Overall P
Cecumececum 6(42.9) 5(35.7) 5(33.3) 1(6.7)* 1(6.7)* 0.034
Cecum-fatty tissue 9(64.3) 5(35.7) 2(13.3)** 6(40) 3(20)* 0.039
Cecum- abdominal wall 5(35.7) 1(7.1)* 1(6.7)* 1(6.7)* 1(6.7)* 0.014
Cecum-liver 2(14.3) 2(14.3) 0(0) 1 (6.7) 2(13.3) 0.61
Cecum-small intestine 11(78.6) 4(28.6)** 4(26.7)** 1(6.7)** 1(6.7)** 0.001
*P < 0.05 vs. group C. **P < 0.01 vs. group C. Signiﬁcant P values are marked in bold.
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any clinical or experimental study analyzing the effectiveness and
safety of a novel anti-adhesive product needs to be compared with
the outcomes after Sepraﬁlm use.
Intra-abdominal adhesions are formed as a result of a dynamic
mechanism. Peritoneal inﬂammation caused by a peritoneal injury
leads to the formation of an inﬂammatory exudate which contains
strands of ﬁbrin. The ﬁbrinogenetic mechanism after this step is
very similar to that which happens during coagulation.2,15,16 Thus,
using anticoagulant products (i.e. low molecular weight heparin
[LMWH]) seems to be a bright idea for adhesion prevention, and it
has been shown in experimental setting that LMWH may stop or
slow down the adhesiogenesis.17,18 Heparin is another anticoagu-
lant product and has been widely used in clinical practice for the
prevention and treatment of deep venous thrombosis. It is an
acidic, anionic, sulfated glycosaminoglycan with molecular weight
of 6000e20000. Only a part of the molecule in commercial use
contains a speciﬁc pentasaccharide sequence which is responsible
for binding to antithrombin III (AT-III). This process results in
conformational changes in AT-III causing a multifold increase in its
ﬁbrin inhibitory potential. This heparin-AT-III complex also causes
inhibition of activated coagulation factors IX, X, XI, and XII. Heparin
has also some anticoagulant actions independent from AT-III,
such as Heparin Cofactor II binding to prothrombin, direct binding
to coagulant factors, and release of some endogenous anticoagu-
lant glycosaminoglycans. In addition to anticoagulant properties,
heparin has also well known anti-inﬂammatory effects which
include anticomplement activity and inhibition of histamine,
serotonine and endothelin-1 release from mast cells.19 Since, it
theoretically reduces ﬁbrin formation and inﬂammation, hepa-
rin has been extensively monitored for adhesion prevention in
laboratory setting.8 These investigations have revealed that heparin
signiﬁcantly reduces postoperative adhesions, but the high risk
of bleeding limits its routine use for this purpose.9 A recent
study from our institution has showed that 500 IU heparin might
be as effective as Sepraﬁlm in preventing postoperative adhe-
sions in a murine model. However, in that study, mortality
secondary to intra-abdominal bleeding was signiﬁcantly higher in
heparin group.20 Since there may be an optimal dose whichTable 4




(n ¼ 14) (%)
Group H62.5
(n ¼ 14) (%)
Group H125
(n ¼ 15) (%)
Group H250
(n ¼ 15) (%)
Group S
(n ¼ 15) (%)
0 0(0) 4(28.6) 8(53.3) 9(60) 9(60)
1 1(7.1) 5(35.7) 1(6.7) 3(20) 4(26.7)
2 6(42.8) 4(28.6) 4(26.7) 2(13.3) 1(6.7)
3 4(28.6) 0(0) 1(6.7) 1(6.7) 1(6.7)
4 3(21.4) 1(7.1) 0(0) 0(0) 0(0)
5 0(0) 0(0) 1(6.7) 0(0) 0(0)
Overall P < 0.001. P < 0. 01 for all groups vs. group C. P < 0.05 for Group H62.5 vs.
group S. P  0.05 for all other comparisons.
a Location score was the total number of adhesion-positive locations among the 5
investigated sites: between cecum and cecum (cecum over itself). cecum and fatty
tissue. cecum and small intestine. cecum and abdominal wall; cecum and liver.decreases the adhesion severity without increasing the risk of
bleeding, we believe that different dosages deserve to be rean-
alyzed as an anti-adhesive product particularly addressing the side-
effects heparin. Current study aims to investigate the effectiveness
and safety of three different dosages of heparin (62.5 IU, 125 IU and
250 IU) and compare the outcomes with those of Sepraﬁlm use
in a murine setting.
Current study has revealed that heparin is an effective and safe
anti-adhesive material. Through the adhesion prevention per-
spective, our data have revealed that both 125 IU, and 250 IU of
heparin use gave similar results to Sepraﬁlm application (P > 0.05
for all comparisons). Although Sepraﬁlm was better than the
lowest dose of heparin use (62.5 IU) in a single comparison, the
statistical difference was borderline (P ¼ 0.042), and was not
repeated in other calculations. Most importantly, all three different
dosages of heparin application gave better results than the control
group in almost all comparisons. Although no statistical difference
was observed between three different dosages of heparin use, the
anti-adhesive effect seems to be increasing by higher doses. Thus,
we believe that all three dosages of heparin may effectively reduce
the intensity of postoperative intra-abdominal adhesions as well
as Sepraﬁlm.
Drug use generally produces numerous results, but one of them
is the primary goal of treatment, which is called as the desired
effect. The undesired (adverse) effects may appear with different
dosages, and the gap between minimum efﬁcient concentrations of
desired and adverse effects is named as therapeutic window, which
reﬂects the concentration range that provides efﬁcacy without
causing undesired toxicity.21 While the amount of drug is being
increased, the intensity of desired effect generally escalates by an
optimum dose, but stops at a level and does not rise even by more
dosages. However, the severity of the side-effects continues to
rise and sometimes even death may happen. The desired effect of
heparin in the current and similar studies is adhesion prevention,
and the main undesired toxicities are bleeding and related
mortality. In a recent study from our institution has shown that 500
IU of heparinmayeffectively reduce intra-abdominal adhesions, but
cause bleeding and consequent mortality.20 In the current study,
lower dosages of 62.5 IU, 125 IU and 250 IU were used, and our
results denied any drug-related complications. However, although
current data showed that mentioned dosages of heparin are safe
and do not cause bleeding, we believe that further experimental
studies are necessitated to evaluate the safety of heparin, since 500
IU of heparin only 2, 4 and 8 times more of that used in the current
study may cause severe bleeding and statistically signiﬁcant more
mortality in our previous study.21 In other words, the therapeutic
window of heparin for adhesion prevention is still unknown, and
deserves to be reanalyzed.
A ﬁnal question to be answered is the appropriate analysis of
the current data for a possible application of the heparin use in
human beings for intra-abdominal adhesion prevention. Heparin
seems to be a promising anti-adhesive product, which has been
proven in different animal studies; but, in our opinion, further
experimental analyses are necessitated before planning a clinical
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minimum anti-adhesive and lethal doses is quite small and the
accurate therapeutic window is still unclear; thus the optimal
dosage should be investigatedwhether or not lower doses of heparin
is as effective as the dosages used in the current study. Secondly, the
calculation of optimal dose for humans may be difﬁcult since the
capacities of abdominal cavity in mice and human are different.
Thus, bigger animals such as dogs or pigs may be preferred during
further studies. On the other hand, as LMWH has taken place of
heparin in the prophylaxis of deep venous thrombosis since it does
not require a close monitoring, it may be a good idea to compare this
product with different dosages of heparin in the future studies.5. Conclusions
Our study has shown that heparin is an effective and safe
product for adhesion prevention in a murine model. All three
dosages are as effective as Sepraﬁlm for adhesion prevention, but
higher doses of use seem to bemore effective. Further experimental
studies are necessary to determine the optimal dosage of intra-
abdominal heparin use for humans in the perspectives of safety
and effectiveness.
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